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Abstract
Background—The perception of cognitive decline by individuals and those who know them well 
(“informants”) has been inconsistently associated with objective cognitive performance, but 
strongly associated with depressive symptoms.
Objective—We investigated associations of self-report, informant-report, and discrepancy 
between self- and informant-report of cognitive decline obtained from the Cognitive Change Index 
(CCI) with cognitive test performance and self-reported depressive symptoms.
Methods—267 participants with normal cognition, mild cognitive impairment (MCI), or mild 
dementia were included from a cohort study and memory clinic. Association of test performance 
and self-rated depression (Geriatric Depression Scale, GDS) with CCI scores obtained from 
subjects (CCI-S), their informants (CCI-I), and discrepancy scores between subjects and 
informants (CCI-D; CCI-S minus CCI-I) were analyzed using correlation and analysis of 
covariance (ANCOVA) models.
Results—CCI-S and CCI-I scores showed high internal consistency (Cronbach alpha 0.96 and 
0.98, respectively). Higher scores on CCI-S and CCI-I, and lower scores on the CCI-D, were 
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associated with lower performance on various cognitive tests in both univariate and in ANCOVA 
models adjusted for age, gender, and education. Adjustment for GDS slightly weakened the 
relationships between CCI and test performance but most remained significant.
Conclusion—Self- and informant-report of cognitive decline, as measured by the CCI, show 
moderately strong relationships with objective test performance independent of age, gender, 
education, and depressive symptoms. The CCI appears to be a valid cross-sectional measure of self 
and informant perception of cognitive decline across the continuum of functioning. Studies are 
needed to address the relationship of CCI scores to longitudinal outcome.
Keywords
Alzheimer’s disease; cognitive change Index; cognitive performance; subjective cognitive decline; 
validation
INTRODUCTION
Individuals in preclinical stages of Alzheimer’s disease (AD) often self-perceive decline in 
their cognition more than a decade prior to a subsequent diagnosis of mild cognitive 
impairment (MCI) or dementia due to AD [1]. This self-perception of decline often plateaus 
or reverses as the illness progresses to dementia [2, 3]. The term subjective cognitive decline 
(SCD) has been used to describe this self-perceived decline in cognition over time [2]. 
Longitudinal studies have shown that cognitively normal individuals with SCD are at a 
higher risk to progress to MCI or dementia [4–6].
There is evidence that SCD is associated with increased likelihood of biomarker 
abnormalities consistent with AD, including findings from cerebrospinal fluid (CSF), 
structural and functional magnetic resonance imaging (MRI), positron emission tomography 
(PET), and visual contrast sensitivity [7–16]. However, the associations between SCD and 
concurrent performance on objective cognitive tests have been inconsistent across studies. 
Since it is acknowledged that depression, anxiety, and personality factors may affect the 
perception of cognitive decline and objective cognitive performance [2, 17–21], these 
variables might contribute to the inconsistent results regarding the relationship between SCD 
and objective cognitive performance.
Confirmation of cognitive decline by an informant was not considered necessary for the 
classification of SCD in the initial consensus definition [2]. However, there is increasing 
evidence that report of one’s cognitive decline by family members or any other close 
observer correlates better with objective cognitive performance than self-report [22, 23] and 
may be a better predictor of subsequent conversion to MCI or dementia [24–26]. 
Additionally, compared to informant-only or self-only report of cognitive decline, using 
mutual report by both subjects and informants has been found to give an even better 
prediction of cognitive decline, with report of decline by both self and informant shown to 
be associated with an additive degree of risk for dementia [27, 28].
The discrepancy between self and informant reports of cognitive decline can be interpreted 
as under- or over-estimation of one’s cognitive problems by the subject in relation to the 
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informant. Limited data has been published to date examining the discrepancy between self 
and informant reports of cognitive decline and their relationship to objective cognitive 
performance. Edmonds et al. examined this relationship by using the discrepancy score 
obtained from self- minus informant-report of the measurement of Everyday Cognition 
(ECog) questionnaire in a cohort that included cognitively normal and MCI participants, and 
demonstrated that amnestic MCI subjects who underestimate their decline relative to their 
informants on ECog memory items show worse performance on an objective recall memory 
test [29]. Moreover, they also demonstrated that underestimation of cognitive problems was 
associated with CSF AD biomarkers and progression to dementia. So, instead of using 
reports of cognitive decline from self-only or informant-only, difference scores from these 
two reports may show a better relationship to objective cognitive performance or predict the 
risk of cognitive decline.
The Cognitive Change Index (CCI) is a tool used to assess the perception of cognitive 
decline in memory, executive function, and language domains from both self and informant 
perspectives. The present 20 item version of the CCI was adapted from a larger item pool 
used in previous research on cognitive complaints in older adults by Saykin et al. [8] with 
item selection based primarily on considerations regarding targeted content within and 
across the three included domains (episodic memory, executive function, and language) as 
well as analyses (unpublished data) on associations with neuroimaging, cognitive and 
outcome variables in an independent sample. The CCI Self and Informant questionnaires are 
available on request from the authors (contact Dr. Saykin at asaykin@iupui.edu). The 
memory items from the self-report of the CCI are also used in the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) cohort study as a criterion to identify subjects with 
significant memory concern [10] (also see http://www.adni-info.org). The current study aims 
to examine the association of CCI scores, obtained from participants and their informants, 
with objective cognitive performance measures, as well as study their association with 
subjectively rated depression, in a mixed sample of individuals with normal cognition, MCI, 
and mild dementia. In addition to using the CCI scores reported by self-only or informant-
only in our analyses, we also used the difference score obtained from self- minus informant-
reports as a proxy measure for the subjects’ insight into their cognitive deficits (excessive 
worry/overestimation versus lack of insight/underestimation) and examined its relationship 
with cognition, which has received limited attention in prior studies. Finally, we investigated 
the effect of depressive symptoms on the association between CCI scores and objective 
cognitive performance.
MATERIALS AND METHODS
Setting and participants
The study was approved by the Indiana University (IU) Institutional Review Board before 
data access and analysis. We collected data from participants with Mini-Mental State 
Examination (MMSE) ≥18 from the local National Institute on Aging-Indiana Alzheimer 
Disease Center (IADC) cohort and the Memory Clinic (MC) of the IU Health Neuroscience 
Center between January 2013 and November 2014. Individuals who are enrolled in the 
IADC are volunteer participants recruited via a variety of mechanisms, including community 
Rattanabannakit et al. Page 3
J Alzheimers Dis. Author manuscript; available in PMC 2017 February 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
outreach and advertisements, clinical referral, and participation in studies of familial genetic 
disorders. Patients seen in the MC are initially evaluated due to clinical memory concerns 
and may present with problems in other domains as well. After excluding subjects with 
incomplete CCI data, 267 adults and their informants were included. Demographic, family 
history, medical history, and neuropsychological assessment data were collected.
Clinical diagnoses of normal cognition, MCI, or dementia were determined by consensus 
between two or more clinicians. Cognitively normal participants (CN) were defined as 
having no deficit in instrumental activities of daily living and no evidence of objective 
cognitive impairment. Diagnosis of MCI was based upon the Petersen criteria [30] and 
defined as having a report of cognitive change by the participant, informant, and/or clinician 
with objective cognitive impairment greater than 1.5 standard deviations outside the age-
adjusted normative mean in at least one cognitive domain and intact instrumental activities 
of daily living. Diagnosis of dementia was based upon standard criteria for dementia of the 
Alzheimer’s type or for other non-Alzheimer’s dementing disorders including DSM-IV [31], 
NINCDS-ADRDA [32] for diagnosis of AD, NINDS-AIREN criteria for the diagnosis of 
vascular dementia [33], Neary consensus on clinical diagnosis criteria for frontotemporal 
lobar degeneration [34] and McKeith’s criteria for the clinical diagnosis of dementia with 
Lewy bodies [35].
Cognitive and behavioral assessments
Participants underwent detailed neuropsychological evaluation, including measures of 
general cognition, memory, language, attention, executive function, and visuospatial ability. 
Only cognitive tests results obtained within three months of the CCI were included in the 
analysis. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) battery 
of neuropsychological tests [36] was used in the MC, while another extensive battery of tests 
including those from the National Alzheimer’s Coordinating Center (NACC) Uniform Data 
Set was used in the IADC cohort. The test batteries shared the MMSE [37], Animal Fluency 
[38], Constructional Praxis [39] and Trail Making Test (Parts A and B) [40]. The CERAD 
incorporates a shorter 15-item Boston Naming Test (BNT) [36] while the full 60-item BNT 
[41] was used in the IADC cohort. Notably, the two study subject sources used different 
verbal learning tests: The Rey Auditory Verbal Learning Test (RAVLT) [42] was used in the 
IADC cohort while the CERAD’s word list memory, recall, and recognition test was used in 
the MC. The CERAD’s word list memory test was also used in some IADC participants in 
addition to the RAVLT. While the Geriatric Depression Scale (GDS) was used in both 
settings, the shorter 15-item GDS [43] was used in the IADC cohort, while the longer 30-
item GDS [44] was used in the MC. As all items in the short 15-item scale were included in 
the 30-item scale, we transformed the 30-item GDS score into 15-item GDS score using 
each response in individual items and used only the 15-item GDS score in the present 
analysis.
Cognitive change index
The CCI consists of two parallel sets of 20 items asking participants and their informants to 
rate the participant’s cognitive function compared to the previous five years. Participants and 
informants were asked to complete the CCI by responding to each item on a 1 to 5 Likert 
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scale with higher scores indicating greater decline (1 = no change or normal ability, 2 = 
minimal change or slight/occasional problem, 3 = some change or mild problem, 4 = clearly 
noticeable change or moderate problem, 5 = much worse or severe problem). 12 of the 20 
CCI items focus on memory performance (e.g., “recalling information when I really try”, 
“remembering things that have happened recently”), 5 of the 20 items evaluate one’s 
executive function (e.g., “focusing on goals and carrying out a plan”), and 3 of the 20 items 
evaluate language (e.g., “understanding conversations”). In the informant-report, there are 
also questions asking about the informant’s relationship to the participant, including average 
number of hours per week spent with participant, number of years he/she has known the 
participant, and confidence in the accuracy of his/her rating. All but one participant and 240 
out of 267 informants completed the CCI during in-person visits. The remaining subject/
informants completed the questionnaire elsewhere and mailed it in.
The sum of all 20 items of the CCI self-report (CCI-S, range 20 to 100) and the CCI 
informant-report (CCI-I, range 20 to 100) were used in this study. The difference score 
between self and informant reports (CCI-D, range −80 to 80) was calculated as CCI-S minus 
CCI-I to demonstrate the discrepancy between self- and informant-reports. A positive value 
on the CCI-D indicates that the participant reported more severe cognitive impairment than 
his or her informant, while a negative value indicates that the informant reported greater 
cognitive impairment than the participant did.
Statistical analysis
Descriptive statistics of baseline clinical characteristics were calculated for all participants, 
including frequency and percentage for categorical variables and mean and standard 
deviation for continuous variables. Clinical characteristics, including age, gender, race, years 
of education, family history of dementia, diagnosis, CCI scores, and neuropsychological 
performance scores were compared between recruitment sites (IADC versus MC) using t-
tests for continuous variables and Fisher’s exact tests for categorical variables. CCI scores 
and cognitive test scores were also compared between recruitment sites and diagnostic 
groups using analysis of covariance models (ANCOVA) adjusted for age, education, gender, 
and diagnosis. Following a significant overall effect, pair-wise comparisons were similarly 
made and p-values were adjusted using Sidak’s multiple comparison method. Associations 
between CCI-S, CCI-I, and CCI-D scores and objective cognitive tests scores and GDS 
scores were assessed using Pearson’s correlation coefficients. Partial correlation coefficients 
derived from ANCOVA models adjusted for various combinations of age, gender, education, 
GDS, and family history of dementia were also calculated to show the association after 
eliminating the influence of these covariates. Because of differences in the cognitive 
assessment by cohort, we calculated Z-scores for the different BNTs and verbal learning 
tests to combine participants from different cohorts in the analysis. The data used to 
standardize the 60-item BNT and the RAVLT came from the first exposure to the test of CN 
participants from the entire population of the IADC. The data used to standardize the 15-
item BNT and the CERAD learning and delayed recall came from the control subjects in 
Morris et al [36]. Statistical analyses were performed using SAS version 9.4.
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RESULTS
Participant and informant demographic characteristics
There were 170 (63.7%) participants from the IADC cohort and 97 (36.4%) from the MC. 
Demographic and cognitive comparisons of the two cohorts can be seen in Table 1. The 
mean age of all participants was 67.8 ± 11.2 years (range 25.1–91.0 years) and 51.7% were 
female. There was no difference in age between participants from the two cohorts, but the 
IADC cohort had a significantly greater proportion of females. The mean education of all 
participants was 15.6 ± 2.8 years. IADC participants were significantly more educated than 
participants from the MC. 139 (52.1%) of all participants had a family history of dementia in 
at least one parent. Participants from the IADC had a significantly higher proportion of 
parental history of dementia compared to those from the MC. Overall, 149 (55.8%) 
participants were classified as CN, 96 (36.0%) had a diagnosis of MCI, and 22 (8.2%) had a 
diagnosis of dementia. The MCI diagnoses consisted of single-domain amnestic MCI 
(44.8%), multiple-domain amnestic MCI (47.9%), and non-amnestic MCI (7.3%). AD was 
the main clinical diagnosis in participants with dementia (50.0%), followed by 
frontotemporal dementia (22.7%), and dementia with Lewy bodies (13.6%). There was a 
significant difference in the diagnoses between participants from the IADC and the MC. 
Most participants from the IADC (75.9%) were CN, whereas most participants from the MC 
(73.2%) had the clinical diagnosis of MCI.
Most informants were the participant’s spouses or partners (66.9%), followed by children 
(20.2%), and others (12.9%), including friends, siblings, and other relatives. The mean time 
that informants spent with participants was 75.4 ± 60.4 hours per week, and they had known 
participants for a mean of 38.8 ± 15.9 years. 65.3% of all informants rated their confidence 
in the accuracy of their CCI evaluation as very high, 31.4% as good, 2.5% as low, and 0.8% 
as very low.
Performance characteristics of CCI and objective neuropsychological performance
Participants from the MC had significantly higher CCI-S and CCI-I scores than participants 
from the IADC (Table 1). These differences remained significant even after adjusting for 
age, gender, education, diagnosis, family history of dementia, and GDS (p = 0.0117 for CCI-
S; p = 0.0001 for CCI-I).
After adjusting for age, gender, education, and diagnosis, no difference in cognitive test 
performance or GDS score was found between participants from IADC and the MC (p ≥ 
0.05) except for the BNT, where participants from the IADC had significantly higher scores 
(p = 0.0001).
Internal consistency of CCI-S and CCI-I and association between these reports
Cronbach alpha scores were 0.96 for the CCI-S and 0.98 for the CCI-I, suggesting good 
internal consistency. CCI scores obtained from subjects and informants were moderately 
correlated with each other (r = 0.53, p < 0.0001). Looking within CCI-I and CCI-S 
separately, the scores obtained from memory, executive function, and language subscales 
were significantly correlated with the total score and each subscale score (rs from 0.71 to 
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0.98, all p < 0.0001, Supplementary Table 1). The subjective subscale scores were also 
significantly correlated with the informant subscale scores (rs from 0.38 to 0.53, all p < 
0.0001).
CCI scores in each diagnostic subgroup
CCI scores from participants and informants were lowest in the CN group compared to the 
MCI or dementia groups, as expected (all p < 0.0001, except p = 0.04 for CCI-S between 
CN and MCI) (see Table 2 and Fig. 1). CCI-I scores were significantly higher in those with 
dementia (p = 0.03) compared to MCI, whereas the CCI-S did not show a significant 
difference between these two diagnosis subgroups (p = 0.97). CCI-D scores were observed 
to be positive in the CN subgroup, but the opposite (i.e., CCI-I > CCI-S) was seen in 
participants with MCI or dementia. Significantly lower CCI-D scores were found in 
participants with dementia compared to those in the MCI (p = 0.01) and CN (p < 0.0001) 
groups. Participants with MCI also had significantly lower CCI-D scores (p < 0.0001) than 
those in the CN group.
Association of CCI scores with neuropsychological test performance
Univariate analysis showed that CCI-S and CCI-I were significantly correlated (all p < 
0.001; Table 3) with objective tests of global cognition (MMSE, r = −0.27 and −0.43), 
spatial ability (Constructional Praxis, r = −0.28 and −0.26), memory (Z-score of verbal 
learning tests; total learning and delayed recall scores, rs from −0.47 to −0.31), processing 
speed and executive function (Trail Making Test Parts A and B, seconds to complete, rs from 
0.36 to 0.45) and language (Z-score of Boston Naming Test, Animal Fluency, rs from −0.46 
to −0.28). Higher CCI-S or CCI-I scores were associated with poorer cognitive performance. 
CCI-D showed significant (p < 0.05) but weaker correlations than CCI-S or CCI-I with all 
cognitive tests except for Constructional Praxis (p = 0.57). As expected, all significant 
associations between CCI-D and cognitive performance were in the opposite direction 
compared to the relation of CCI-S and CCI-I scores (r = −0.16 and −0.15 for Trail Making 
Test Parts A and B, and r = 0.19 to 0.26 for other cognitive tests) corresponding to loss of 
insight into one’s cognitive deficits among the cognitively impaired. Significant positive 
associations were shown between the GDS and both the CCI-S (r = 0.56, p < 0.0001) and 
CCI-I (r = 0.39, p < 0.0001), but not between GDS and CCI-D (p = 0.41). Adjustments for 
age, gender, and education did not meaningfully alter the pattern of findings with the 
exception of the relationship of CCI-D to the Trail Making Test Part A and B which was 
rendered non-significant.
Effect of depressive symptoms on the association of CCI scores and objective cognitive 
performance
Most of the relationships between CCI scores and objective cognitive test performances 
reported above were slightly attenuated but remained significant after adjusting for 
depressive symptoms as measured by the GDS, except for the relationship between CCI-D 
and Trail Making Test Part B, which was rendered non-significant (see Table 4). The 
relationship between CCI-S and MMSE was also attenuated to non-significant after 
adjusting for age, gender, education, and GDS score.
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DISCUSSION
This study reports on the internal consistency and initial concurrent validity of the Cognitive 
Change Index in a mixed sample of cognitively normal, MCI, and demented participants 
drawn from a tertiary care memory clinic and a research-based Alzheimer Disease Center. 
Participant and informant ratings of cognitive impairment on the CCI showed good internal 
consistency and were related to objective cognitive test scores even after adjusting for 
demographics and depressive symptoms. Construct validity in the context of the CCI 
addresses the coherence of the overall cognitive change concept based on self or informant-
perceived changes in cognition. One relevant type of external validity can be demonstrated 
by the correlation of each subscale score with objective tests in the same cognitive domain. 
We found that subscales of the CCI are highly correlated with objective tests in the same 
domain, but also correlate with objective tests in other domains. This finding may suggest 
that a given cognitive complaint may stem from impairment in more than one domain, 
highlighting the challenge of developing cognitive tests or questionnaires that are “pure” 
measures of a function.
As expected, participant CCI scores were lowest in the cognitively normal group and 
elevated in the MCI and dementia groups, which did not differ from each other. Also as 
expected, informant report of cognitive impairment progressively increased across 
diagnostic groups with the lowest scores reported for cognitively normal participants and 
highest scores for demented participants. Lastly, the CCI discrepancy score (CCI-D) showed 
a clear trend for increasing distance between informant and participant ratings (informant > 
participant) with increasing cognitive impairment, likely reflecting a progressive 
deterioration in insight or awareness among participants.
Similar to previous studies, our study demonstrated that self-perceived cognitive decline was 
highly correlated with psychological symptoms [16, 19, 21, 45–47], and informant-report of 
subject’s cognitive decline correlated better than self-report to objective cognitive tests [22, 
23]. We used the GDS to assess depressive symptoms in our study. Although the GDS may 
be not an accurate test for depression in patients with dementia [48], evidence has shown 
that the validity of the GDS depends on the degree of cognitive impairment, such that more 
severe cognitive impairment may reduce the sensitivity of the GDS in detection of 
depression [49, 50]. In our study, the mean MMSE is quite high (mean MMSE was 28.2 
± 1.9). Even in our demented participants, who were mostly at a mild level, the mean 
MMSE was 25.5 ± 3.1. It is very likely that the GDS is valid for this specific application in 
our study.
The CCI-D had the weakest association with cognitive test scores but it was the only score 
that was not associated with the GDS. As the CCI-I showed the strongest relationship to 
objective cognitive performance among the various CCI metrics examined, it may be the 
most valid score to use in assessing an individual’s perceived cognitive decline, especially in 
later symptomatic stages of disease. However, there is evidence that level of awareness in 
subjects with different levels of cognitive impairment (controls, MCI, AD) varies among 
studies within and between clinical or research-based settings [51]. As our MCI participants 
had average negative value for CCI-D scores (indicating CCI-I was worse than CCI-S), this 
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could reflect reduced awareness in our MCI sample and attenuate the association of CCIS 
and objective cognitive tests. Future studies in other populations may show different results 
for the correlation between self- and informant-report of cognitive decline and cognitive 
tests, and such differences may be informative with regard to the role of sample 
characteristics such as insight and awareness. Furthermore, we also demonstrated that GDS 
scores can slightly weaken the relationship of the CCI with objective cognitive performance, 
suggesting that CCI-I scores adjusted for GDS score may be preferred to minimize the 
influence of depressive symptoms. Alternatively, if GDS or similar data is unavailable, the 
CCI-D might be preferable to use in analyses, as it was not significantly associated with the 
GDS. The use of discrepancy scores appears promising and warrants further study.
CCI-S and CCI-I scores were higher in participants from the MC even after adjusting for 
several potentially important covariates. It is possible that there is a higher level of concern 
in participants from the MC, which is a medical help-seeking setting, compared to the 
IADC, which is a clinical research-based setting, resulting in higher CCI ratings for MC 
participants. Unfortunately, no specific independent data was available from subjects or 
informants regarding level of memory concern that would permit us to investigate this 
question further.
A high proportion of our participants had a family history of dementia in at least one parent, 
which was highest in participants from the IADC. This is likely attributable to greater 
motivation of individuals with family history of dementia to volunteer for dementia-related 
research relative to those without such a history. There is limited evidence regarding whether 
genetic variation affects the concurrent perception of cognitive decline or objective cognitive 
performance. Risacher et al. examined the effect of APOE ε4 genotype on cognitive 
complaints, objective cognitive performance, and various AD imaging and CSF biomarkers 
in participants with normal cognition, SCD and early MCI [10]. They found that APOE ε4 
status was not associated with cognitive complaints, but did associate significantly with 
selected measures of memory and executive performance across diagnostic groups. To 
investigate the effect of family history of dementia, we used it as a covariate in a multivariate 
model (also adjusted for age, gender, and education), and found that none of the 
relationships of CCI scores and objective cognitive performance were significantly altered 
(Supplementary Table 2).
Among various objective cognitive associations included in our study, only performance on 
the BNT was significantly superior in participants from the IADC relative to patients from 
the MC after accounting for the influence of age, gender, education, and diagnosis. However, 
there is evidence that BNT scores are significantly correlated with estimated verbal 
intelligence as measured by the Wechsler Adult Intelligence scale–Revised (1981) 
Vocabulary subtest score or the Gates-MacGinitie Reading Vocabulary Test [52, 53]. As we 
did not include these tests in our sample, we cannot rule out verbal ability as a factor 
accounting for the BNT difference between participants from IADC and the MC. However, 
regarding the significant difference of BNT Z-scores between the two sources of our 
participants, we investigated the effect of sample (IADC versus MC) by adding it as a 
covariate in multivariable models, and found that all associations between the CCI and Z-
score of BNT were still significant (all p < 0.01) (Supplementary Table 3).
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There are some limitations to our study. First, this is a cross-sectional study so we could not 
determine whether CCI scores predict actual decline or disease progression. Future studies 
of the CCI are needed to address test-retest reliability of each form, the relationships to AD 
biomarkers, rate of clinical progression, and longitudinal outcomes. These data are needed to 
establish the utility for risk determination and other clinical applications. It should be also 
noted that self- and informant measures of perceived cognitive decline may be differentially 
associated with AD biomarkers and cognitive outcomes in a stage-specific manner, i.e., the 
pattern of associations may change over the course of progression from normal cognition to 
MCI or dementia. Secondly, even though our statistical analyses demonstrated that age did 
not influence our results, on average our participants were relatively young, so these findings 
may not be generalizable to studies of older individuals. Third, apart from depressive 
symptoms, we did not have information regarding other psychological or personality 
variables. Evidence suggests that a subject’s anxiety, long-standing personality traits, and/or 
meaning-in-life also influence SCD [2, 19–21, 45, 54]. Further, it should be noted that 
informant-reported CCI may be affected by psychological conditions or personality traits of 
informants as well. Future studies that include more extensive psychological and personality 
measures in both subjects and informants are warranted.
In conclusion, the CCI shows good internal consistency and moderately strong relationships 
with objective cognitive performance, and as such appears to be a valid cross-sectional 
marker of self and informant perception of cognitive decline across the continuum of 
cognitive function. Future research is needed to determine the relationship of subjective and 
informant report of cognitive function to longitudinal outcome. Prospective longitudinal 
cohort studies including the CCI along with AD biomarker measurement in individuals at 
risk for MCI and dementia would likely provide valuable mechanistic data regarding stage-
specific sensitivity and specificity.
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Fig. 1. 
Box plot showing the performances of each CCI score in each diagnostic subgroup. CCI, 
Cognitive Change Index; CCI-S, Self-report score of CCI; CCI-I, Informant-report score of 
CCI; CCI-D, Difference in CCI score from self-report minus informant-report; CN, 
cognitively normal; MCI, mild cognitive impairment.
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